![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
J Schmider, DJ Greenblatt, LL von Moltke, JS Harmatz and RI Shader
Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston Massachusetts, USA.
Biotransformation of amitriptyline (AMI) to its demethylated product nortriptyline (NT) was studied in vitro with human liver microsomes from four different donors, preselected to reflect a range of metabolic rates. Reaction velocity versus substrate concentration was consistent with a sigmoid Vmax model. Vmax varied from 0.42 to 3.42 nmol/mg/min, Km from 33 to 89 microM AMI. Ketoconazole was a highly potent inhibitor of N-demethylation, with a mean Ki value of 0.11 +/- 0.013 microM (+/- S.D.), whereas quinidine (up to 50 microM), a CYP2D6 inhibitor, and alpha-naphthoflavone (up to 5 microM), a CYP1A2 inhibitor only at low concentrations, showed no effect. All selective serotonin reuptake inhibitors (SSRIs) tested had an inhibitory effect on the formation of NT, with mean Ki values of 4.37 (+/- 3.38) microM for sertraline, 5.46 (+/- 1.95) microM for desmethylsertraline, 9.22 (+/- 3.69) microM for fluvoxamine, 12.26 (+/- 5.67) microM for norfluoxetine, 15.76 (+/- 5.05) microM for paroxetine, and 43.55 (+/- 18.28) microM for fluoxetine. A polyclonal rabbit antibody against rat liver CYP3A1, in antibody/microsomal protein ratios varying from 1:1 to 10:1, inhibited N-demethylation of AMI to an asymptotic maximum of 60%. These results are consistent with several case reports describing impairment of AMI metabolism by SSRIs. Inhibition of AMI demethylation by low concentrations of ketoconazole and by anti-3A antibody supports an important role for CYP3A isoforms in mediating this reaction.
This article has been cited by other articles:
|
|
 |
|
  X. Pan, F. N. Hussain, J. Iqbal, M. H. Feuerman, and M. M. Hussain Inhibiting Proteasomal Degradation of Microsomal Triglyceride Transfer Protein Prevents CCl4-induced Steatosis J. Biol. Chem., June 8, 2007; 282(23): 17078 - 17089. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Kalgutkar, T. J. Taylor, K. Venkatakrishnan, and E. M. Isin Assessment of the Contributions of CYP3A4 and CYP3A5 in the Metabolism of the Antipsychotic Agent Haloperidol to Its Potentially Neurotoxic Pyridinium Metabolite and Effect of Antidepressants on the Bioactivation Pathway Drug Metab. Dispos., March 1, 2003; 31(3): 243 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Venkatakrishnan, L. L. von Moltke, and D. J. Greenblatt Application of the Relative Activity Factor Approach in Scaling from Heterologously Expressed Cytochromes P450 to Human Liver Microsomes: Studies on Amitriptyline as a Model Substrate J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 326 - 337. [Abstract] [Full Text]
|
|
|
|
|
|
K. Venkatakrishnan, L. L. von Moltke, R. S. Obach, and D. J. Greenblatt Microsomal Binding of Amitriptyline: Effect on Estimation of Enzyme Kinetic Parameters In Vitro J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 343 - 350. [Abstract] [Full Text]
|
|
|
|
|
|
J. B. Houston and K. E. Kenworthy In Vitro-In Vivo Scaling of CYP Kinetic Data Not Consistent with the Classical Michaelis-Menten Model Drug Metab. Dispos., March 1, 2000; 28(3): 246 - 254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Witherow and J. B. Houston Sigmoidal Kinetics of CYP3A Substrates: An Approach for Scaling Dextromethorphan Metabolism in Hepatic Microsomes and Isolated Hepatocytes to Predict In Vivo Clearance in Rat J. Pharmacol. Exp. Ther., July 1, 1999; 290(1): 58 - 65. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. Ouellet, A. Hsu, J. Qian, J. E. Lamm, J. H. Cavanaugh, J. M. Leonard, and G. R. Granneman Effect of Fluoxetine on Pharmacokinetics of Ritonavir Antimicrob. Agents Chemother., December 1, 1998; 42(12): 3107 - 3112. [Abstract] [Full Text]
|
|
|
|
|
|
D. E. Moody, M. E. Alburges, R. J. Parker, J. M. Collins, and J. M. Strong The Involvement of Cytochrome P450 3A4 in the N-Demethylation of l-alpha -Acetylmethadol (LAAM), norLAAM, and Methadone Drug Metab. Dispos., December 1, 1997; 25(12): 1347 - 1353. [Abstract] [Full Text]
|
|
|
|
|
|
K. Linnet and O. V. Olesen Metabolism of Clozapine by cDNA-Expressed Human Cytochrome P450 Enzymes Drug Metab. Dispos., December 1, 1997; 25(12): 1379 - 1382. [Abstract] [Full Text]
|
|
|
|
|
|
O. V. Olesen and K. Linnet Hydroxylation and Demethylation of the Tricyclic Antidepressant Nortriptyline by cDNA-Expressed Human Cytochrome P-450 Isozymes Drug Metab. Dispos., June 1, 1997; 25(6): 740 - 744. [Abstract] [Full Text]
|
|
|
|
|
|
E. Koyama, K. Chiba, M. Tani, and T. Ishizaki J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1199 - 1210. [Abstract] [Full Text]
|
|
|
|
|
|
H. Yamazaki, W. W. Johnson, Y.-F. Ueng, T. Shimada, and F. P. Guengerich Lack of Electron Transfer from Cytochrome b5 in Stimulation of Catalytic Activities of Cytochrome P450 3A4. CHARACTERIZATION OF A RECONSTITUTED CYTOCHROME P450 3A4/NADPH-CYTOCHROME P450 REDUCTASE SYSTEM AND STUDIES WITH APO-CYTOCHROME b5 J. Biol. Chem., November 1, 1996; 271(44): 27438 - 27444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Xiang, R. A. Tschirret-Guth, and P. R. Ortiz de Montellano An A245T Mutation Conveys on Cytochrome P450eryF the Ability to Oxidize Alternative Substrates J. Biol. Chem., November 10, 2000; 275(46): 35999 - 36006. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
